| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440634 | European Journal of Cancer | 2017 | 7 Pages |
Abstract
Brain metastases develop often, early and frequently as the only site of relapse in the course of poor-prognosis GCT. This raises the question of early detection and optimal treatment of brain metastases in these patients, e.g. by integrating a systematic brain MRI after 2-3 months of chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Y. Loriot, L. Pagliaro, A. Fléchon, J. Mardiak, L. Geoffrois, P. Kerbrat, C. Chevreau, R. Delva, F. Rolland, C. Theodore, G. Roubaud, G. Gravis, J.C. Eymard, J.P. Malhaire, C. Linassier, M. Habibian, A.L. Martin, F. Journeau, K. Fizazi,